Primary sclerosing cholangitis, commonly abbreviated as PSC, is a chronic disease in which the bile ducts—the narrow channels that carry bile from the liver to the intestine—become inflamed and progressively narrowed by scar tissue. As the ducts stiffen and close, bile backs up in the liver, inflicting damage that can culminate in cirrhosis, liver failure, and an elevated risk of cancers of the bile duct and liver. The disease primarily strikes young adults, and its only definitive cure is liver transplantation. Sweden, like the rest of Scandinavia, carries a comparatively high burden of PSC, and yet no drug currently exists that can stop or reverse its course. Against this backdrop of therapeutic helplessness, any insight into the disease’s underlying biology carries enormous weight.

The connection between PSC and the intestine has long been one of the disease’s defining enigmas. Between 60 and 80 percent of PSC patients also suffer from inflammatory bowel disease, and researchers have repeatedly observed that the gut microbiome of PSC patients differs markedly from that of healthy individuals. These observations fueled a persistent hypothesis: somehow, the bacteria dwelling in the gut were contributing to the destruction of the bile ducts. But the mechanism remained stubbornly invisible. Correlation abounded; causation was nowhere to be found.

The new study, published in Nature Metabolism, points to a potential missing link: a metabolite called imidazole propionate, or ImP. ImP is formed when certain gut bacteria break down dietary components, and it has previously attracted scientific attention for its role in other metabolic diseases. According to the research team, led by Antonio Molinaro, a researcher at the University of Gothenburg and senior consultant hepatologist at Sahlgrenska University Hospital, patients with PSC showed elevated circulating levels of this bacterial metabolite. More strikingly, the concentration of ImP in the blood served as a predictor of clinical outcomes: patients with higher levels faced poorer survival prospects over time.

But the researchers did not stop at association. In experiments with mice, they demonstrated that chronic administration of imidazole propionate was sufficient to induce liver inflammation, mimicking key features of the human disease. This was a pivotal step, because it transformed ImP from a mere biomarker into a plausible causal agent. If a bacterial metabolite can provoke liver inflammation in a living organism, the long-suspected gut-liver axis in PSC acquires a concrete molecular foundation.

The study also illuminated how the damage occurs at the cellular level. When ImP encounters the cholangiocytes—the protective cells that line the bile ducts—it triggers activated signaling within these cells that drives both inflammation and fibrosis. Fibrosis, the excessive deposition of hard scar tissue, is the process that renders organs stiff and dysfunctional, and in PSC it is precisely the mechanism by which the bile ducts progressively lose their function. By identifying the specific molecular pathway through which ImP acts, the researchers have supplied what Molinaro describes as a potential biological explanation for the connection between gut bacteria and PSC.

“The study suggests that PSC may arise when metabolites produced by an altered gut microbiota continuously reach and damage the bile ducts,” Molinaro explains. “The results thus provide a potential biological explanation for the long-suspected link between gut bacteria and PSC. Importantly, we also identified the molecular pathway underlying these effects.”

That last point—the identification of a defined molecular pathway—is what elevates the findings from intriguing observation to potential therapeutic roadmap. In modern medicine, knowing that a factor is involved in a disease is only half the battle; the true prize is an actionable target. ImP offers several such targets simultaneously. “This opens up several possible future avenues for treatment: reducing the bacterial production of ImP, inhibiting the bacterial enzymes responsible for its production, or blocking the signaling pathway through which ImP appears to cause damage,” says Molinaro.

Each of these strategies represents a distinct therapeutic frontier. Reducing bacterial production of ImP might be achieved through dietary interventions or microbiome-directed therapies designed to reshape the gut ecosystem. Inhibiting the specific bacterial enzymes that convert dietary precursors into imidazole propionate would represent an approach somewhere between an antibiotic and a metabolic drug—precisely targeting microbial chemistry while sparing the broader bacterial community. And blocking the downstream signaling pathway in the bile duct cells would constitute a classic drug-development strategy, one that pharmaceutical researchers could pursue with small molecules designed to interrupt the inflammatory cascade before it scars the ducts.

The researchers are careful, however, not to overstate the case. ImP is not presented as the sole cause of PSC. The disease is widely understood to arise from a complex interplay of genetic susceptibility, immunological dysfunction, and environmental triggers, layered on top of changes in the gut microbiota. PSC does not respond to immunosuppressive therapies the way many other autoimmune or inflammatory conditions do, which has long hinted that its drivers are unusual and multifactorial. The new findings do not overturn that picture; rather, they suggest that ImP may be one significant contributor among several—a thread that, when pulled, explains a substantial part of the clinical presentation of the disease.

Even so, the implications are profound. For a disease with no approved medical therapy, the identification of a circulating, microbiome-derived metabolite that both correlates with disease severity and can induce liver pathology in animal models is a rare and valuable advance. It reframes PSC not merely as an autoimmune attack on the bile ducts, but as a disease in which the metabolic output of an altered gut ecosystem acts as a continuous, low-grade assault on the liver’s drainage system. Every meal, in this view, feeds the bacteria; the bacteria feed the production of ImP; and the ImP, absorbed into the portal circulation, travels directly to the liver and its bile ducts.

The portal vein, which carries nutrient-rich blood from the intestine to the liver, is precisely why the gut-liver axis is so consequential. The liver is the first major organ to encounter everything the gut absorbs, and the bile ducts are intimately exposed to this traffic. A microbial metabolite that survives digestion and absorption therefore has a direct route to the very tissue it damages. The Gothenburg study gives this anatomical reality a molecular protagonist.

The path from mouse experiments to human therapy is, of course, long and uncertain. Clinical trials will need to establish whether lowering ImP levels in patients—or interrupting its signaling—slows the progression of fibrosis and improves survival. Biomarker studies will need to confirm whether ImP can serve as a reliable prognostic tool, allowing clinicians to identify which patients are at greatest risk of deterioration. And the microbiome science will need to determine which bacterial species and enzymes are responsible for ImP production, and how they might be selectively restrained without wholesale disruption of a gut ecosystem that health depends upon.

Yet the study’s publication in Nature Metabolism signals that the scientific community regards these findings as a substantive contribution. For patients with PSC—a population that includes many young adults facing a progressive disease with a transplant as their only escape—the research offers something that has been in short supply: a concrete, mechanistic explanation for their illness, and several plausible routes toward the first effective medical treatment.

The work also resonates beyond PSC. Imidazole propionate has been implicated in insulin resistance and other metabolic conditions, and the study adds to a growing body of evidence that microbial metabolites are not passive byproducts of digestion but active chemical messengers capable of reshaping the biology of distant organs. The liver, positioned at the gateway between gut and body, appears particularly vulnerable to these molecular messengers—and, perhaps, particularly amenable to therapies that target them.

For now, the discovery stands as a testament to the power of interdisciplinary research, bridging hepatology, microbiology, and metabolomics. A molecule forged by bacteria in the dark of the intestine, the study suggests, may hold the key to understanding—and one day treating—one of the liver’s most intractable diseases.

Liver fibrosis is a pathophysiological condition marked by excessive accumulation of extracellular matrix proteins, primarily due to chronic liver injury from factors including excessive alcohol consumption, viral hepatitis, and fatty liver disease. This scarring process disrupts normal liver architecture and function, ultimately risking progression to cirrhosis, liver failure, and hepatocellular carcinoma. Despite liver fibrosis affecting a significant fraction of the global population—estimated at 3 to 4 percent in its advanced stages—effective targeted treatments remain scarce, representing a critical unmet medical need.

At the cellular level, hepatic stellate cells (HSCs) play a vital role in the maintenance of liver homeostasis. Under physiological conditions, these cells remain in a quiescent state, storing vitamin A and supporting normal liver architecture. However, sustained liver injury activates HSCs, transforming them into proliferative, fibrogenic myofibroblast-like cells. These activated HSCs excessively produce fibrous collagen and other matrix components, perpetuating scarring and impairing liver function. Hence, targeting activated HSCs has become a focal point in therapeutic strategies aiming to halt or reverse fibrosis.

The research team, led by Associate Professor Tsutomu Matsubara and Dr. Atsuko Daikoku at Osaka Metropolitan University’s Graduate School of Medicine, pioneered a novel chemical screening methodology to directly identify substances capable of modulating HSC activation. Through this advanced high-throughput screening process, they isolated Lawsone—a naphthoquinone compound naturally occurring in henna tree leaves—as a potent inhibitor of HSC activation pathways.

In vivo studies using murine models of liver fibrosis treated with Lawsone demonstrated a significant reduction in hallmark fibrotic biomarkers. Levels of Yes-associated protein (YAP), alpha-smooth muscle actin (αSMA), and collagen type 1 alpha 1 (COL1A) were markedly decreased, indicating suppression of pro-fibrogenic signaling and extracellular matrix deposition. Furthermore, the treated HSCs exhibited increased expression of cytoglobin (CYGB), a protein associated with antioxidant defense and the quiescent state of stellate cells, suggesting that Lawsone helps revert fibrogenic cells back toward their non fibrotic, dormant phenotype.

Mechanistically, Lawsone appears to exert its antifibrotic effect by modulating YAP signaling pathways within HSCs. YAP is a transcriptional coactivator implicated in cellular proliferation and fibrosis progression. By inhibiting YAP pathway activation, Lawsone prevents excessive collagen synthesis and mitigates fibrotic tissue buildup. Concurrently, the induction of CYGB expression enhances oxidative stress resilience in HSCs, further contributing to the restoration of their homeostatic roles and inhibiting ongoing fibrogenesis.

This dual modulation of both fibrotic signaling and antioxidant response by Lawsone opens new avenues for therapeutic interventions that surpass current treatments, which primarily aim to manage symptoms rather than reverse fibrosis. Indeed, the researchers posit that Lawsone-based drugs could constitute the first pharmacological strategy that not only controls but potentially improves established liver fibrosis, offering hope to millions of patients worldwide.

Recognizing the translational value of their findings, the Osaka Metropolitan University team is currently developing sophisticated drug delivery systems intended to selectively transport Lawsone to activated HSCs with high efficiency. By optimizing targeted delivery, they aim to enhance therapeutic potency while minimizing off-target effects and systemic toxicity, a crucial consideration for chronic liver disease therapies.

The implications of this research also extend beyond liver fibrosis. Since fibroblast activation is a common pathological feature in various fibrotic diseases affecting organs such as the lungs, kidneys, and heart, controlling fibroblast behavior via principles elucidated from Lawsone’s mechanism may herald broader anti-fibrotic applications. Such cross-organ therapeutic potential underscores the transformative nature of targeting cellular pathways involved in fibrosis.

Published in the peer-reviewed journal Biomedicine & Pharmacotherapy, this study not only advances our understanding of liver fibrosis pathogenesis but also exemplifies the innovative repurposing of natural compounds from traditional sources for cutting-edge medical applications. The findings elevate henna from a mere cosmetic dye to a promising pharmacological agent with life-saving potential.

As the global burden of liver disease continues to rise, largely driven by lifestyle-related factors, the urgency for effective anti-fibrotic therapies cannot be overstated. The discovery of Lawsone’s inhibitory effect on fibrogenic HSCs presents a beacon of hope, offering a scientifically sound and potentially practical approach to drastically improving liver health outcomes. Further clinical studies are anticipated to validate these preclinical results and accelerate the translation to human therapeutics.

Looking forward, the collaborative efforts of pharmacologists, molecular biologists, and clinical scientists will be instrumental in refining Lawsone-based treatments, including formulating oral or injectable pharmacokinetics suitable for chronic administration. Success in such endeavors can redefine the therapeutic landscape for liver fibrosis, transforming a previously irreversible condition into a manageable or even reversible disease state.

In conclusion, the research from Osaka Metropolitan University pioneers a novel intervention pathway by harnessing the bioactive components of a centuries-old natural dye. This breakthrough underscores the untapped potential residing within traditional natural products, inspiring continued exploration of natural substances for addressing complex modern health challenges such as liver fibrosis. The translation of Lawsone into clinical use heralds a promising future in precision medicine for liver diseases.

Subject of Research: People

Article Title: Lawsone can suppress liver fibrosis by inhibition of YAP signaling and induction of CYGB expression in hepatic stellate cells

News Publication Date: 4-Sep-2025

Web References: http://dx.doi.org/10.1016/j.biopha.2025.118520

Image Credits: Osaka Metropolitan University

Keywords: Liver fibrosis, Hepatic stellate cells, Lawsone, Lawsonia inermis, YAP signaling, Cytoglobin, Antifibrotic therapy, Natural compounds, Drug development, Liver disease, Fibrosis reversal